Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3‐Month results from the TRIUMPH study

Key Points

• This research aims to compare the effectiveness of galcanezumab and traditional oral migraine preventive medications in reducing monthly migraine days.
• Compared monthly migraine days after 3 months between galcanezumab and TOMP medications
• Involved adult patients starting or switching to either treatment
• Patients receiving galcanezumab experienced a greater reduction in monthly migraine days than those on TOMP medications
• The findings suggest that galcanezumab may be more effective in real-world scenarios